We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ENGI:EURONEXT PARISENGIE S.A. Analysis

Data as of 2026-03-11 - not real-time

€27.04

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Engie's stock currently trading at €27.04, just above its 20‑day SMA (27.01) and comfortably above the 50‑day SMA (25.35), indicating short‑term bullish momentum. The 200‑day SMA sits at €21.12, underscoring a longer‑term uptrend. Technicals show a neutral RSI of 54.5 and a bearish MACD histogram (‑0.23) with the signal line above the MACD line, suggesting some near‑term downside pressure. Volume is increasing, and the price sits near the identified support of €25.45 and well below the resistance at €29.89, leaving upside potential of roughly 1.6 %. The Fear & Greed Index reads “Extreme Greed” (76.9), reflecting strong market appetite.
On the fundamentals side, Engie trades at a forward‑PE of 13.4 versus an industry average of 20.7, implying the stock is undervalued. The dividend yield of 5.14 % and a payout ratio of 73 % are attractive, though operating cash flow (‑€1.48 bn) and free cash flow (‑€0.70 bn) are negative, raising questions about dividend sustainability. Leverage is high, with total debt of €55.2 bn and a debt‑to‑equity of 135 %, while the balance sheet holds €19.3 bn of cash. Revenue is contracting (‑6.6 % YoY) but margins remain solid (gross 31.9 %, operating 10.5 %). The company’s diversified global footprint and push into renewables provide a defensible long‑term narrative despite short‑term cash‑flow strains.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price above short‑term SMAs
  • support level near €25.45
  • bearish MACD signal

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • valuation gap vs industry peers
  • high dividend yield
  • negative operating cash flow

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • strategic renewable expansion
  • stable utility demand
  • attractive dividend despite leverage

Key Metrics & Analysis

Financial Health

Revenue Growth-6.60%
Profit Margin5.32%
P/E Ratio13.3
ROE11.54%
ROA2.90%
Debt/Equity135.16
P/B Ratio2.3
Op. Cash Flow€-1476000000
Free Cash Flow€-703249984
Industry P/E20.7

Technical Analysis

TrendBullish
RSI54.5
Support€25.45
Resistance€29.89
MA 20€27.01
MA 50€25.35
MA 200€21.12
MACDBearish
VolumeIncreasing
Fear & Greed Index76.91

Valuation

Target Price€27.48
Upside/Downside1.61%
GradeUndervalued
TypeValue
Dividend Yield5.14%

Risk Assessment

Beta0.15
Volatility34.62%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.